PAVmed Inc PAVM.OQ PAVM.O is expected to show a fall in quarterly revenue when it reports results on August 13 for the period ending June 30 2025
The New York City-based company is expected to report a 99.0% decrease in revenue to $10 thousand from $979 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for PAVmed Inc is for a loss of 13 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for PAVmed Inc is $11.50, about 96% above its last closing price of $0.46
This summary was machine generated August 11 at 20:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)